PET-CT在卵巢癌中的临床应用价值

董孟杰; 林祥通; 赵军

PET-CT在卵巢癌中的临床应用价值

董孟杰 , 林祥通 , 赵军

文章导航 > 国际放射医学核医学杂志 > 2005, 29 > 5: (209-213)

引用本文:

Citation:

PET-CT在卵巢癌中的临床应用价值

200040 上海, 复旦大学附属华山医院核医学科
中图分类号: R814.42;R817.4

The application of PET-CT in ovarian cancer

Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
CLC number: R814.42;R817.4

摘要: 卵巢癌是妇科较常见的恶性肿瘤及致死原因,正电子发射体层显像(PET)对于卵巢癌的诊断、分期、复发及疗效监测及预后方面优于常规的检测手段(CT、MRI及肿瘤标志物检查);PET-CT对指导手术有重要价值;特异性PET显像剂的研制已取得初步成果,¹²⁴I-C6.5 diabody已经成功用于动物的PET-CT。
- 卵巢癌 /
- 正电子发射体层显像 /
- 计算机体层成像 /
- ¹⁸F-氟代脱氧葡萄糖
Abstract: Ovarian cancer is the leading cause of death among women with gynecologic malignancies, ¹⁸F-fluorodeoxyglucose (¹⁸SF-FDG) positron emission tomography (PET) is a well-established method for detecting, staging, cancer recurrence and therapeutic response and prognosis of ovarian cancer. PET-CT is helpful for the surgry guide and second-look laparotomy. Specific radiolabel pharmacies to ovarian cancer such as ¹²⁴I-C6.5 diabody has been successfully imaged in animal with PET-CT.
- ovarian carcinoma /
- positron emission tomography /
- computed tomography /
- ¹⁸F-fluorodeoxyglucose
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fiuorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary[J]. Int J Cancer,2004, 109(6):926-932.
[2]	Torizuka T, Kanno T, Futatsubashi M, et al. Imaging of gynecologic tumors:comparison of (11)C-choline PET with (18)F-FDG PET[J].J Nucl Med,2003, 44(7):1051-1056.
[3]	Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody[J]. Cancer Res, 2005,65(4):1471-1478.
[4]	Nishizawa S, Inubushi M, Okada H. Physiological ¹⁸F-FDG uptake in the ovaries and uterus of healthy female volunteers[J]. Eur J Nucl Med Mol Imaging, 2005, 32(5):549-556.
[5]	Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence:role of whole-body positron emission tomography using2-[fluorine-18]-fluoro-2-deoxy-D-glucose[J]. Eur J Nucl Med Mol Imaging, 2002, 29(6):797-803.
[6]	Nakamoto Y, Saga T, Ishimori I, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer[J]. Am J Roentgenol, 2001, 176(6):1449-1454.
[7]	Menzel C, Dobert N, Hamscho N, et al. The influence of CA 125and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer[J]. Strahlenther Onkol, 2004, 180(8):497-501.
[8]	Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer[J]. Gynecol Oncol,2005, 97(1):183-191.
[9]	Kim EE. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology[J]. Int J Gynecol Cancer, 2004, 14(1):12-22.
[10]	Unger JB, Ivy JJ, Connor P, et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women[J]. Gynecol Oncol, 2004, 94(1):212-216.
[11]	Chang WC, Hung YC, Lin CC, et al. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels-a preliminary report[J]. Cancer Invest,2004, 22(2):180-184.
[12]	Makhija S, Howden N, Edwards R, et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma:a retrospective review[J].Gynecol Oncol, 2002, 85(1):53-58.
[13]	Bristow RE, delCarmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer:patient selection for secondary cytoreduc-tive surgery usingcombinedPET/CT[J]. GynecolOncol, 2003, 90(3):519-528.
[14]	Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer[J]. Gynecol Oncol, 1994, 53(5):331-338.
[15]	Rose PG, Faulhaber P, Miraldi F, et al. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma:correlation with second-look laparotomy[J]. Gynecol Oncol, 2001, 82(1):17-21.
[16]	Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer[J]. Gynecol Oncol, 2001, 83(2):310-315.
[17]	Miller TR, Grigsby PW. Measurement oftumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treat-ed by radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2002, 53(2):353-359.
[18]	Barranger E, Kerrou K, Petegnief Y. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer[J]. Gynecol Oncol, 2005, 96(1):241-244.
[19]	Smith GT, Hubner KF, McDonald T, et al. Cost analysis of FDG PET for managing patients with ovarian cancer[J]. Clin Positron Imaging, 1999, 2(2):63-70.

[1]	吴湖炳 . ¹⁸F-氟代脱氧葡萄糖PET-CT在头颈部肿瘤中的应用价值. 国际放射医学核医学杂志, 2005, 29(5): 205-209.
[2]	华逢春 , 管一晖 , 赵军 . ¹⁸F-氟代脱氧葡萄糖PET及PET-CT在淋巴瘤中的临床应用. 国际放射医学核医学杂志, 2005, 29(5): 216-219,226.
[3]	刘建军 , 黄钢 . ¹⁸F-氟代脱氧葡萄糖PET和PET-CT在转移性骨肿瘤中的应用研究. 国际放射医学核医学杂志, 2005, 29(5): 213-216.
[4]	季仲友 . PET-CT中诊断性CT的必要性与临床应用. 国际放射医学核医学杂志, 2005, 29(5): 197-200.
[5]	陈香 , 赵军 , 管一晖 . PET-CT常见伪影. 国际放射医学核医学杂志, 2005, 29(5): 201-205.
[6]	蔡莉 , 李彦生 . 氟代脱氧葡萄糖与氨基酸PET在脑肿瘤中的对比研究. 国际放射医学核医学杂志, 2005, 29(1): 10-14.
[7]	王峰 . ¹⁸F-FDG PET对原发性食管癌和复发性食管癌的诊断价值. 国际放射医学核医学杂志, 2004, 28(1): 15-17.
[8]	袁志斌 . 正电子肿瘤阳性显像剂¹⁸F-AMT. 国际放射医学核医学杂志, 2002, 26(5): 193-195.
[9]	陈永辉 , 李方 . 双探头符合线路¹⁸F-FDG显像在肺癌诊断中的作用. 国际放射医学核医学杂志, 2002, 26(6): 260-262,267.
[10]	温广华 . ¹⁸F-FDG PET显像在肝癌中的应用. 国际放射医学核医学杂志, 2003, 27(1): 21-24.

点击查看大图

计量

文章访问数: 1083
HTML全文浏览量: 112
PDF下载量: 2

PET-CT在卵巢癌中的临床应用价值

200040 上海, 复旦大学附属华山医院核医学科

收稿日期: 2005-07-08

关键词:

摘要: 卵巢癌是妇科较常见的恶性肿瘤及致死原因,正电子发射体层显像(PET)对于卵巢癌的诊断、分期、复发及疗效监测及预后方面优于常规的检测手段(CT、MRI及肿瘤标志物检查);PET-CT对指导手术有重要价值;特异性PET显像剂的研制已取得初步成果,¹²⁴I-C6.5 diabody已经成功用于动物的PET-CT。